Diamandis, PhediasFerrer-Luna, RubenHuang, Raymond Y.Folkerth, Rebecca D.Ligon, Azra H.Wen, Patrick Y.Beroukhim, RameenLigon, Keith L.Ramkissoon, Shakti H.2019-10-052016Diamandis, Phedias, Ruben Ferrer-Luna, Raymond Y. Huang, Rebecca D. Folkerth, Azra H. Ligon, Patrick Y. Wen, Rameen Beroukhim, Keith L. Ligon, and Shakti H. Ramkissoon. 2016. “Case Report: Next Generation Sequencing Identifies a NAB2-STAT6 Fusion in Glioblastoma.” Diagnostic Pathology 11 (1). https://doi.org/10.1186/s13000-016-0455-9.1746-1596http://nrs.harvard.edu/urn-3:HUL.InstRepos:41483001Background: Molecular profiling has uncovered genetic subtypes of glioblastoma (GBM), including tumors with IDH1 mutations that confer increase survival and improved response to standard-of-care therapies. By mapping the genetic landscape of brain tumors in routine clinical practice, we enable rapid identification of targetable genetic alterations.Case Presentation: A 29-year-old male presented with new onset seizures prompting neuroimaging studies, which revealed an enhancing 5 cm intra-axial lesion involving the right parietal lobe. He underwent a subtotal resection and pathologic examination revealed glioblastoma with mitoses, microvascular proliferation and necrosis. Immunohistochemical (IHC) analysis showed diffuse expression of GFAP, OLIG2 and SOX2 consistent with a tumor of glial lineage. Tumor cells were positive for IDH1(R132H) and negative for ATRX. Clinical targeted-exome sequencing (DFBWCC Oncopanel) identified multiple functional variants including IDH1 (p.R132H), TP53 (p.Y126_splice), ATRX (p.R1302fs*), HNF1A (p.R263H) and NF1 (p.H2592del) variants and a NAB2-STAT6 gene fusion event involving NAB2 exon 3 and STAT6 exon 18. Array comparative genomic hybridization (aCGH) further revealed a focal amplification of NAB2 and STAT6. IHC analysis demonstrated strong heterogenous STAT6 nuclear localization (in 20 % of tumor cells). Conclusions: While NAB2:STAT6 fusions are common in solitary fibrous tumors (SFT), we report this event for the first time in a newly diagnosed, secondary-type GBM or any other non-SFT. Our study further highlights the value of comprehensive genomic analyses in identifying patient-specific targetable mutations and rearrangements.en-USJournal Article2019-10-0510.1186/s13000-016-0455-9